

Supplemental Table S1. Sequences of the primers for qPCR analysis.

Gene	Primers	Sequence (5'-3')
GAPDH	Forward	CCTCGTCCCGTAGACAAAATG
	Reverse	TGAGGTCAATGAAGGGGTCGT
IL-2	Forward	TCACCCTTGCTAATCACTCCTC
	Reverse	TCCTGTAATTCTCCATCCTGCT
IL-4	Forward	GATAAGCTGCACCATGAATGAGT
	Reverse	CCATTTGCATGATGCTCTTTAGG
IL-18	Forward	AGACCTGGAATCAGACAACCTTTGG
	Reverse	GGGTCACAGCCAGTCCTCTT
IFN- γ	Forward	CTCAAGTGGCATAGATGTGGAAG
	Reverse	TGACCTCAAACCTGGCAATACTC
TNF- α	Forward	CCCTCACACTCACAAACCACC
	Reverse	CTTTGAGATCCATGCCGTTG
IL-10	Forward	AATAAGCTCCAAGACCAAGGTGT
	Reverse	CATCATGTATGCTTCTATGCAGTTG

Supplemental Table S2. Statistical comparison of cytotoxic effects among eight treatment groups of in-vitro experiments.

Cytotoxic effects	Control	RFH	L-315	RFH+L-315	DOX	RFH+DOX	L-315+DOX	RFH+L-315+DOX
Necrotic / Apoptotic cells	5.5%±1.4%	6.9%±1.2%	51.8%±2.7%	70.7%±2.3% #	49.6%±2.3%	71.4%±2.4% &	81.0%±2.2% †	95.5%±1.6% *
Cell viability	100%±0.0%	96.2%±3.3%	50.2%±4.8%	32.4%±2.6% #	50.1%±2.2%	33.8%±4.2% &	19.1%±2.7% †	10.3%±2.1% *
Relative BS	100%±0.0%	96.5%±1.9%	49.6%±2.6%	22.9%±1.7% #	50.0%±2.2%	27.9%±1.9% &	11.1%±1.5% †	5.1%±0.6% *

BS: bioluminescence signal

*: $p < 0.001$ (The triple treatment group of RFH + LTX-315 + liposomal doxorubicin versus other seven treatment groups)

#: $p < 0.001$ (The group of RFH+LTX-315 versus LTX-315 alone)

&: $p < 0.001$ (The group of RFH+DOX versus DOX alone)

†: $p < 0.001$ (The group of L-315+DOX versus L-315 alone or DOX alone)

Supplemental Table S3. Statistical comparison of imaging findings among eight groups of in-vivo experiments.

Imaging findings	Control	RFH	L-315	RFH+L-315	DOX	RFH+DOX	L-315+DOX	RFH+L-315+DOX
Baseline TV (mm ³)	133.45±26.61	132.31±34.29	129.79±23.56	125.69±15.55	129.00±26.91	127.17±20.15	124.03±23.91	127.43±35.48
Relative PS	3.29±0.28	3.28±0.24	0.63±0.02	0.44±0.03 #	0.80±0.02	0.56±0.02 &	0.26±0.04 †	0.06±0.03 *
Relative TV	3.26±0.19	3.25±0.23	0.72±0.02	0.44±0.02 #	0.80±0.03	0.54±0.02 &	0.25±0.03 †	0.04 ± 0.02 *

TV: tumor volume; PS: photon signals.

*: $p < 0.001$ (The triple treatment group of RFH + LTX-315 + liposomal doxorubicin versus other seven treatment groups)

#: $p < 0.001$ (The group of RFH+LTX-315 versus LTX-315 alone)

&: $p < 0.001$ (The group of RFH+DOX versus DOX alone)

†: $p < 0.001$ (The group of L-315+DOX versus L-315 alone or DOX alone)

Supplemental Table S4. Statistical comparison of pathology confirmation among eight treatment groups of in-vivo experiments.

Pathology confirmation	Control	RFH	L-315	RFH+L-315	DOX	RFH+DOX	L-315+DOX	RFH+L-315+DOX
Relative TW	23.55±4.06	22.93±3.88	12.05±1.12	7.17±0.40 #	12.90±0.88	7.87±0.45 &	4.49±0.53 [†]	1.00±0.00 *
Apoptotic cells (×10 ⁶ IOD)	0.94±0.17	0.97±0.09	3.66±0.24	7.51±0.32 #	3.59±0.19	7.42±0.36 &	12.54±0.94 [†]	27.29±1.25 *
Proliferating cells (×10 ⁷ IOD)	2.78±0.19	2.71±0.15	1.86±0.09	1.25±0.07 #	1.91±0.12	1.25±0.05 &	0.93±0.04 [†]	0.67±0.08 *
Tumor necrosis rate	5.5%±1.4%	6.9%±1.2%	51.8%±2.7%	70.7%±2.3% #	49.6%±2.3%	69.2%±2.1% &	81.1%±2.2% [†]	95.5%±1.6% *

TW: Tumor weights

*: $p < 0.001$ (The triple treatment group of RFH + LTX-315 + liposomal doxorubicin versus other seven treatment groups)

#: $p < 0.001$ (The group of RFH+LTX-315 versus LTX-315 alone)

&: $p < 0.001$ (The group of RFH+DOX versus DOX alone)

[†]: $p < 0.001$ (The group of L-315+DOX versus L-315 alone or DOX alone)